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The International Psoriasis Genetics Study: Assessing Linkage to 14
Candidate Susceptibility Loci in a Cohort of 942 Affected Sib Pairs
The International Psoriasis Genetics Consortium*
In an effort to confirm previously reported linkages to psoriasis, we analyzed 942 affected sibling pairs (ASPs) from
710 pedigrees for 53 polymorphic microsatellites spanning 14 psoriasis candidate regions at an intermarker spacing
of ∼5 cM. Maximum LOD score (MLS) analysis of ASPs yielded allele sharing of 60% for markers within the
major histocompatibility complex (MHC) ( ), which yielded a gene-specific ls of 1.6. Across the
514Pp 2# 10
remainder of the genome, the strongest evidence of allele sharing was obtained on chromosomes 16q (D16S3032;
; ) and 10q22–q23 (D10S2327; ; ). None of the remaining loci exceededMLSp 1.3 Pp .007 MLSp 1.1 Pp .012
, the value expected to occur by chance once in this study. In agreement with previous studies, strongMLSp 0.9
linkage disequilibrium was also observed between psoriasis and the MHC (pedigree disequilibrium test Pp
for D6S1014). Two psoriasis-associated MHC haplotypes were identified with the haplotype-based583.9# 10
transmission/disequilibrium test. Analysis of only those families carrying either of these haplotypes significantly
increased the chromosome 16q LOD score from 1.3 to 2.4 ( ). These results underscore the importancePp .045
of the MHC in psoriasis and provide a rationale for more-detailed examination of candidate regions on chromosomes
16q and 10q.
Psoriasis (MIM 177900) is an inflammatory, hyperpro-
liferative disorder of the skin, the pathogenesis of which
remains poorly understood (Barker 1998; Elder 1998).
Psoriasis is common, affecting 12% of adults in most
populations, yet current therapeutic strategies remain
suboptimal (Camp 1998). Susceptibility to the devel-
opment of psoriasis has a significant genetic component,
with the ls, a measure of the risk ratio of disease in
siblings of affected subjects, reported to be in the range
4–6 (Bhalerao and Bowcock 1998; Elder et al. 2001).
Psoriasis appears to be a disorder of complex etiology
that requires the interaction of unknown environmental
triggers and genetic susceptibility (Elder et al. 2001; Ca-
pon et al. 2002). Resolution of the molecular genetic
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contributions to the pathogenesis of psoriasis will pro-
vide a logical framework against which future advances
in treatment and/or prevention are likely to evolve. In
recent years, a number of genomewide linkage scans
have been performed, by use of family material ascer-
tained from dispersed geographical locations. In no
fewer than five studies, significant evidence of linkage
has been reported for PSORS1 (psoriasis susceptibility
1) a region located on the short arm of chromosome 6
and specifically within the major histocompatibility
complex (MHC) (Nair et al. 1997; Trembath et al. 1997;
Samuelsson et al. 1999; Lee et al. 2000; Veal et al. 2001;
Zhang et al. 2002). Further linkage disequilibrium–
mapping studies, including the use of non-MHC gene
polymorphic markers, when taken together, localize
PSORS1 to a genomic segment ∼150 kb in length. This
region includes the class 1 MHC gene HLA-C and the
gene that encodes corneodesmosin, a component of the
keratinocyte desmosome (Balendran et al. 1999; Oka et
al. 1999; Nair et al. 2000). Intensive genetic studies to
identify risk haplotypes from this region are now under
way (Nair et al. 2000; Veal et al. 2002). However, initial
assessment of allele sharing between affected sibling
pairs suggests that the PSORS1 locus may account for
no more than 50% of the sibling relative risk (Trembath
et al. 1997), which supports the view that, in addition
Reports 431
Table 1
The Consortium Data Set: Sample Composition
Cohort No. of Pedigrees No. of ASPs Origin
London/Leicester/Glasgow 228 349 United Kingdom
Ann Arbor/Kiel 244 361 United States, Germany
Dallas/St. Louis 238 232 United States
Total 710 942
Table 2
The Consortium Data Set: Pedigree Structures
NO. OF AFFECTED SUBJECTS
FAMILY TYPE NO. OF FAMILIES 1 2 3 4 5 6 7
Nuclear 566 38 320 176 31 2 1 0
Extended 144 0 14 43 29 26 12 18
Total 710 38 334 219 60 28 13 18
to potential environmental triggers for disease onset, sus-
ceptibility is dependent on the role of other genetic loci.
To date, at least seven regions outside of the MHC
(PSORS2–8) have been proposed to harbor psoriasis
susceptibility loci, on the basis of genomewide linkage
scans (Tomfohrde et al. 1994; Matthews et al. 1996;
Nair et al. 1997; Capon et al. 1999; Samuelsson et al.
1999; Lee et al. 2000; Veal et al. 2001). Support for a
putative susceptibility locus is greatly enhanced by rep-
lication (at a statistically significant level) in independent
data sets. Indeed, this process is perceived as a critical
strategy to aid distinction from false-positive linkages,
in the data sets generated by marker-dense genomewide
analyses (Lander and Kruglyak 1995). An alternative
strategy is to analyze very large samples (Risch 2000).
This strategy is aimed at overcoming the low power
inherent in diseases characterized by low-penetrance,
high-prevalence susceptibility loci. All such studies re-
quire careful attention to population selection so as to
minimize the effects of ethnic and clinical heterogeneity.
To better understand the genetics of psoriasis, we have
established a consortium of investigators to investigate
14 previously reported potential psoriasis-susceptibility
loci in a cohort of 710 families with psoriasis. Although
the subjects have been ascertained across broad geo-
graphical regions, the vast majority of patients and rela-
tives are of European descent.
Subjects.—The International Psoriasis Genetics Con-
sortium patient cohort consists of independently ascer-
tained pedigrees, providing a total of 942 affected sib
pairs (ASPs). Details are presented in table 1 and table
2. All families were recruited by experienced consortium
members (based in Dallas/St. Louis; Ann Arbor/Kiel,
Germany; and London/Leicester/Glasgow), by use of cri-
teria as described in detail elsewhere (Tomfohrde et al.
1994; Nair et al. 1997; Trembath et al. 1997). The Ann
Arbor/Kiel data set included 221 ASPs typed in a genome
scan performed by Nair and colleagues (1997), together
with a further 140 ASPs recruited for this study. The
London/Leicester cohort included family material de-
scribed by Veal and colleagues (2001), with no dupli-
cation of the data set used by the same group in an initial
genome scan (Trembath et al. 1997). The Dallas/St.
Louis sample comprised 238 pedigrees and specifically
did not include the multiply affected families used in the
scan that localized PSORS2 on 17q (Tomfohrde et al.
1994). The three groups used comparable diagnostic cri-
teria and excluded case subjects where palmo-plantar
pustulosis or seborrheic dermatitis occurred in the ab-
sence of other clinical signs of psoriasis (Camp 1998).
Each group obtained approval for these studies from
its own institutional review board or ethics committee
(U.K.). All subjects participating in this study provided
informed consent.
Genotyping.—The candidate regions were defined as
(i) any locus identified by genome scans published at the
outset of the study and (ii) loci that had displayed sug-
gestive evidence of linkage in at least one genome scan,
including unpublished surveys by Consortium members.
All 14 regions that met these criteria are reported in
table 3. A total of 53 polymorphic microsatellites span-
ning the candidate loci at an average of 5-cM intervals
(table 3) were selected from the Marshfield (Broman et
al. 1998) and Ge´ne´thon (Dib et al. 1996) marker sets.
Genotyping was performed by the London/Leicester and
Dallas/St. Louis groups by use of fluorescent dyes (Trem-
bath et al. 1997), with electrophoresis and signal re-
cording performed on ABI 377 automated sequencers
(Applied Biosystems). The Ann Arbor/Kiel group per-
formed genotyping using 32P labeling of a single primer,
as described elsewhere (Nair et al. 1997). CEPH indi-
vidual 1347-02 was genotyped by all three groups as a
standard for comparison. Completeness of genotyping
varied from group to group and from marker to marker,
with a range of 66%–95% in the pooled sample. Men-
delian inconsistencies in pedigree data were identified
and eliminated by the PedCheck software (O’Connell
and Weeks 1998).
Statistical analyses.—Allele sharing in affected siblings
was assessed by use of Risch’s maximum LOD score
(MLS) method (Risch 1990), as implemented in a mod-
ification of GENEHUNTER 2.1 (Kruglyak et al. 1996;
Markianos et al. 2001). This method employs a 1-df
Table 3
Psoriasis Susceptibility Regions Typed in Consortium Data Set
Region and Marker
Distance from pter
(cM) MLS MAS References
1q21 (PSORS4): Bhalerao and Bowcock 1998; Capon et al. 1999
D1S1679 235.8 .6 .52
APOA2 243.865 .3 .51
D1S1677 245.44 .6 .52
2p: Trembath et al. 1997; Bhalerao and Bowcock 1998
D2S1342 89.375 0 .5
D2S136 90.735 0 .5
D2S134a 105.87 0 .5
D2S1772 106.965 0 .5
4q13: Bhalerao and Bowcock 1998
D4S427 178.775 .3 .52
D4S2394 182.01 .4 .52
4q21: Samuelsson et al. 1999
D4S1548 214.455 .4 .52
D4S1629 221.34 .5 .52
D4S1554 262.02 .2 .51
4qter (PSORS3): Matthews et al. 1996
D4S1535 266.995 .2 .51
D4S171 274.875 .3 .51
6p21 (PSORS1): Nair et al. 1997; Trembath et al. 1997; Samuelsson et al. 1999
TNFB 83.51 12.1 .59
D6S273 84.125 12.6 .59
D6S1014 84.635 12.6 .59
D6S291 84.93 11.1 .59
6q: Nair et al. 1997
D6S270 184.57 .7 .53
GATA184A08 198.07 .4 .52
8q24: Trembath et al. 1997
D8S1128 191.015 0 .5
D8S1801 195.185 0 .51
D8S284 197.495 .1 .51
D8S558 200.56 .2 .51
10q22: Nair et al. 1997
D10S1136 126.955 .9 .53
D10S569 133.365 1.1 .53
D10S2327 137.315 1.1 .53
11p13: Nair et al. 1997
D11S935 81.55 .4 .52
D11S1330 84.915 .4 .52
D11S1360 87.51 .3 .52
D11S903 90.995 .2 .51
14q31: Bhalerao and Bowcock 1998
D14S617 123.68 0 .5
D14S81 128.225 .3 .51
D14S1142 130.735 .1 .51
D14S1434 134.46 0 .5
16q: Nair et al. 1997
D16S3396 91.84 .6 .52
D16S770 92.3 .6 .52
D16S415 96.635 .6 .52
D16S3034 99.625 .6 .52
D16S771 100.38 .5 .52
D16S3032 102.62 1.3 .53
17q25 (PSORS2): Tomfohrde et al. 1994; Nair et al. 1997; Enlund et al. 1999
D17S2059 112.475 .2 .52
D17S1301 122.795 .7 .53
D17S674 141.935 .3 .52
D17S784 161.535 0 .5
D17S668a 179.825 0 .5
D17S928 179.825 0 .5
20p: Nair et al. 1997; Trembath et al. 1997
D20S879 49.915 .1 .51
D20S851 52.12 .1 .51
D20S160 53.985 0 .5
D20S894 57.015 0 .51
D20S186 57.825 0 .5
D20S604 59.92 0 .5
a Markers D2S134 and D17S688 were not typed for the Ann Arbor/Kiel group.
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Table 4
Evidence of Association with Psoriasis in Regions of Linkage Replication
Region Haplotypea Alleles T:NTb Pc
6p21.3 TNFB-D6S273-D6S1014 103-136-136 164:50 6! 1# 10
6p21.3 TNFB-D6S273-D6S1014 113-130-148 88:41 53.5# 10
16q12-q13 D16S770-D16S415-D16S3034 131-208-272 37:10 58.2# 10
a Most-significant GENEHUNTER2 multipoint TDT haplotypes.
b Transmitted:nontransmitted.
c Nominal P values. After performance of empirical permutation testing to address
multiple-allele combinations (by use of GENEHUNTER) and after multiplication by 3
to correct for the number of regions tested with MLS values !1.0 (6p, 10q, and 16q),
the corrected P values are all !.05.
multiplicative MLS test, in which ,p2pMAS#MAS
, andp1p 2#MAS(1MAS) p0p (1MAS)(1
, where “MAS” denotes mean allele sharing. ToMAS)
assess statistical significance of MLS values, 1,000 sim-
ulations of the Consortium cohort were performed by
creating data sets matching the marker-map positions
and allele frequencies, as well as the family structure,
the genotyped individuals, and the missing data per-
centage of the total sample. Simulations were performed
by use of the GENSIM software (available at Dr. Daly’s
Web page; see “Electronic-Database Information”
section).
Association between marker haplotypes and psoriasis
was assessed by the multilocus transmission/disequilib-
rium test (TDT) implementation of GENEHUNTER 2.1.
Association between single markers and psoriasis was
assessed by means of the pedigree-disequilibrium test
(PDT) (Martin et al. 2000, 2001). The published version
of the PDT uses all informative triads and discordant
sibships in a pedigree. We extended the PDT to also use
all informative dyads (one typed parent and affected
child) if no informative triads are present. P values were
determined for a global test of all alleles at each marker,
by use of the PDT-average statistic. All dyads that could
lead to bias in the disequilibrium statistic (Curtis and
Sham 1995) were eliminated.
Possible interactions between PSORS1 and the vari-
ous non-MHC loci were assessed by analyzing a subset
of 250 families in which at least one affected individual
had an obligate or maximum-likelihood three-marker
microsatellite haplotype matching one of the overtrans-
mitted MHC chromosomes identified by the haplotype-
based TDT. For this analysis, MHC haplotypes were
scored as matching when two alleles matched and the
third was ambiguous or missing.
Empirical simulations.—The analysis of 1,000 ran-
dom replicas of the 710 families’ genotypes demon-
strated that an MLS of 2.0 could be expected to occur
by chance, anywhere in the 14 analyzed regions, in5%
of experiments. An MLS 12.0 can therefore be adopted
as a criterion for declaring significant linkage in the con-
text of this study. Our simulations also indicated that
an MLS of 0.9 would be expected to occur by chance
once per experiment and, as such, may be considered as
a value suggestive of linkage in the context of this study
(Lander and Kruglyak 1995).
Linkage analysis results.—A summary of linkage re-
sults is shown in table 3. Analysis of allele sharing at
chromosome 6p21 confirmed the presence of a major
susceptibility locus within the MHC, as documented by
an MLS of 12.6 (marker D6S273; ). Af-14Pp 2# 10
fected sibling pairs displayed allele sharing of 60%,
which corresponds to a gene-specific ls of 1.6 for the
MHC locus.
The strongest evidence of linkage to non-MHC lo-
ci was obtained on chromosomes 10q (MLSp 1.1
for D10S2327; ) and 16q ( forPp .012 MLSp 1.3
D16S3032; ) (table 3). The evidence of link-Pp .007
age at the remaining non-MHC loci failed to reach
the criterion expected to occur by chanceMLSp 0.9
once per study (table 3).
Association analysis results.—Haplotype association
analyses were performed at the regions of linkage rep-
lication. Consistent with prior association studies (re-
viewed by Capon et al. 2002), strong linkage disequi-
librium was observed between psoriasis and alleles
within the MHC. Multipoint TDT analysis indicated
preferential transmission of two MHC haplotypes (table
4). Comparison with data published elsewhere (Nair et
al. 2000) revealed that one of these haplotypes carried
HLA-Cw6 and HLA-B57, and the other carried HLA-
Cw6 and HLA-B13 (data not shown). A putative sus-
ceptibility haplotype could also be defined on chromo-
some 16q (table 4), whereas no evidence of association
could be observed for chromosome 10q markers.
Single-marker linkage disequilibrium testing was also
performed at the regions of linkage replication by use
of the PDT. Again, strong linkage disequilibrium was
observed between psoriasis and MHC markers. The
most highly significant P value was obtained within the
MHC ( for marker D6S1014). The two8Pp 1.3# 10
other MHC markers also yielded P values !.01 (3.4#
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and for TNFB and D6S273, respec-3 310 3.2# 10
tively). Chromosomes 10 and 16 did not yield any single-
marker PDT P values !.3.
Interactions of MHC and non-MHC loci.—To define
putative interactions between the MHC and other sus-
ceptibility loci, we analyzed a subset of 250 families in
which at least one affected individual carried either of the
MHC-risk haplotypes. In this set of families, evidence of
linkage to chromosome 16 increased from toMLSp 1.3
, despite a marked reduction in sample sizeMLSp 2.4
from 710 to 250 families. An increase in MLS from 1.3
to 2.4 in this chromosomal region would occur !5% of
the time by chance, as evaluated by repeated resampling
of the observed data (224/5,000 runs). No other region
yielded in this subgroup.MLS 1 1.5
The International Psoriasis Genetics Consortium Co-
hort represents, to our knowledge, the largest available
collection of families with psoriasis to date. The Con-
sortium was established to allow the analysis of pooled
data sets, by use of common statistical tools and an
agreed-on marker panel, with spacing sufficiently dense
to potentially extract a greater proportion of the inheri-
tance information. Detailed assessment of cohorts of this
size is likely to prove essential in efforts to refine the
likely target genome locations for positional cloning of
susceptibility genes. In this study, we chose to assess in
some detail those regions of the human genome for
which evidence of linkage to a psoriasis-susceptibility
locus had already been observed at the outset of the
study. Our results provided unequivocal evidence of link-
age and allelic association for the susceptibility region
on chromosome 6p21 (PSORS1) (Nair et al. 1997;
Trembath et al. 1997). We identified two MHC hap-
lotypes composed of alleles at loci TNFB-D6S273-
D6S1014, which extend over 0.6 Mb, to be preferen-
tially transmitted to subjects affected by psoriasis. We
and others have recently performed linkage disequilib-
rium studies, using high-resolution microsatellite and
SNP marker maps, and highlighted a 150-kb interval of
conserved association (Balendran et al. 1999; Oka et al.
1999; Nair et al. 2000; Veal et al. 2002). These inves-
tigations have revealed a single likely ancestral risk hap-
lotype, which is present on both of the overtransmitted
chromosomes identified in this study (R. P. Nair, P. E.
Stuart, S. Jenisch, J. T. Elder, C. D. Veal, F. Capon, J.
N. W. N. Barker, and R. Trembath, unpublished data).
The detection of two TNFB-D6S273-D6S1014 haplo-
types that have HLA-Cw6 in common but differing in
their HLA-B alleles is most likely explained by an an-
cestral recombination event between HLA-B and HLA-
C. Further efforts to resolve the psoriasis-susceptibility
allele(s) at PSORS1 by use of the large cohort reported
here, together with ethnically diverse patient popula-
tions, are now under way.
Despite the exceptionally strong linkage signal gen-
erated at the 6p21 region, allele sharing between sib
pairs was no greater than 60%, which suggests that the
MHC locus-specific ls accounts for !50% of the familial
clustering observed in psoriasis. The number and mag-
nitude of effect for additional susceptibility loci for pso-
riasis, and the extent to which they may account for
etiological heterogeneity, is currently unknown. In the
present study, no other locus achieved a genomewide
significance level !.05, equivalent to an allele-sharing
LOD score 13.63 in a genomewide linkage scan (Lander
and Kruglyak 1995). Since this study was designed to
survey a number of regions of the genome for which
prior evidence of linkage had been generated, we were
anxious to avoid loss of potentially important obser-
vations through assessment against criteria put forward
to aid the interpretation of primary genomewide link-
age scans. We therefore developed specific significance
thresholds by performing empirical simulations of the
entire data set. Against these estimates of significance,
we observed two regions on chromosomes 16q and 10q
that provide evidence suggestive of linkage in the context
of this study. However, it should be noted that partial
overlap exists between the families originally studied by
the Ann Arbor/Kiel group (Nair et al. 1997) and those
analyzed here (see “Subjects” section). Elimination of
these families reduced the MLS values for all non-MHC
loci to below the criterion value of (dataMLSp 0.9
not shown). By comparison, markers in the MHC region
continued to yield MLS values as high as 12.3, even after
exclusion of the overlapping Ann Arbor families (data
not shown). Clearly, caution is required in assessing link-
age to the non-MHC regions on 10q and 16q. An even
larger data set will be required to discriminate with con-
fidence between susceptibility loci with a minor effect
and false-negative linkage results.
Notwithstanding these concerns, the involvement of
a chromosomal locus at 16q in psoriasis susceptibility
was supported by the results of MHC interaction analy-
sis, which revealed an increase in MLS from 1.3 to 2.4,
despite a reduction in sample size from 710 to 250 fami-
lies. This change in MLS would be expected to occur in
this chromosomal region !5% of the time by chance.
Moreover, we identified a 2.5-cM haplotype, D16S770-
D16S415-D16S3034, which is significantly overtrans-
mitted to affected offspring with psoriasis (Pp 8.2#
). Some additional evidence of independent repli-510
cation of linkage to this region has recently emerged
through the study of psoriatic subjects whose disease is
complicated by the occurrence of a seronegative arthritis
(Karason et al. 2003). Furthermore, a number of ge-
nomewide scans in a range of disorders that are char-
acterized by an abnormal inflammatory response to
environmental triggers have reported linkage to 16q
(Becker et al. 1998). This region includes CARD15, a
susceptibility gene underlying the inflammatory bowel
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disorder, Crohn disease (Hugot et al. 2001; Ogura et al.
2001). Mutation analysis and lack of association be-
tween CARD15 alleles and psoriasis (Nair et al. 2001;
Borgiani et al. 2002; Young et al., in press) together with
its localization, which is at least 8 cM proximal to the
marker D16S3034, would appear to eliminate CARD15
as a likely psoriasis candidate gene in this region. Taken
together, these findings strengthen the argument for fur-
ther investigation of the 16q region in conferring sus-
ceptibility to psoriasis, since the mechanism is likely to
be distinct from that contributing to Crohn disease.
Given the relatively modest effect of this locus, the Con-
sortium data set is among the very few which are likely
to provide the power required for a reliable refinement
study.
In conclusion, this large collaborative study is likely
to facilitate further research efforts to determine and
characterize susceptibility loci for the common skin dis-
order, psoriasis. These data provide unequivocal evi-
dence of a major role for a gene or genes within the
class 1 region of the MHC. Other loci are likely to con-
fer lower risk to disease causation and, hence, will pose
a considerable challenge for future detection and
characterization.
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